{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:31:14Z","timestamp":1784039474117,"version":"3.55.0"},"reference-count":230,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Atherothrombosis results from direct interaction between atherosclerotic plaque and arterial\nthrombosis and is the most common type of cardiovascular disease. As a long term progressive\ndisease, atherosclerosis frequently results in an acute atherothrombotic event through plaque rupture\nand platelet-rich thrombus formation. The pathophysiology of atherothrombosis involves\ncholesterol accumulation endothelial dysfunction, dyslipidemia, immuno-inflammatory, and apoptotic\naspects. Platelet activation and aggregation is the major cause for stroke because of its roles,\nincluding thrombus, contributing to atherosclerotic plaque, and sealing off the bleeding vessel.\nPlatelet aggregates are associated with arterial blood pressure and cardiovascular ischemic events.\nUnder normal physiological conditions, when a blood vessel is damaged, the task of platelets\nwithin the circulation is to arrest the blood loss. Antiplatelet inhibits platelet function, thereby decreasing\nthrombus formation with complementary modes of action to prevent atherothrombosis. In\nthe present scientific scenario, researchers throughout the world are focusing on the development\nof novel drug delivery systems to enhance patient\u2019s compliance. Immediate responding pharmaceutical\nformulations become an emerging trend in the pharmaceutical industries with better patient\ncompliance. The proposed review provides details related to the molecular pathogenesis of\natherothrombosis and recent novel formulation approaches to treat atherothrombosis with particular\nemphasis on commercial formulation and upcoming technologies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666201027125303","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T06:19:32Z","timestamp":1603865972000},"page":"399-419","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis"],"prefix":"10.2174","volume":"22","author":[{"given":"Selvakumar","family":"Muruganantham","sequence":"first","affiliation":[{"name":"Centre for Excellence in Nanobio Translational Research (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli, Tamil Nadu,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateshwaran","family":"Krishnaswami","sequence":"additional","affiliation":[{"name":"Centre for Excellence in Nanobio Translational Research (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli, Tamil Nadu,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmugarathinam","family":"Alagarsamy","sequence":"additional","affiliation":[{"name":"Centre for Excellence in Nanobio Translational Research (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli, Tamil Nadu,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4125-0244","authenticated-orcid":true,"given":"Ruckmani","family":"Kandasamy","sequence":"additional","affiliation":[{"name":"Centre for Excellence in Nanobio Translational Research (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli, Tamil Nadu,India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.thromres.2019.09.033","volume":"184","author":"Ramacciotti E.","year":"2019","unstructured":"Ramacciotti E.; Weitz J.I.; Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. Thromb Res 2019,184,44-49","journal-title":"Thromb Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.08.005","volume":"113","author":"Chapman M.J.","year":"2007","unstructured":"Chapman M.J.; From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. Pharmacol Ther 2007,113(1),184-196","journal-title":"Pharmacol Ther"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jacc.2013.06.045","volume":"62","author":"Sanz J.","year":"2013","unstructured":"Sanz J.; Moreno P.R.; Fuster V.; The year in atherothrombosis. J Am Coll Cardiol 2013,62(13),1131-1143","journal-title":"J Am Coll Cardiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.beem.2008.12.004","volume":"23","author":"Stratmann B.","year":"2009","unstructured":"Stratmann B.; Tschoepe D.; Atherogenesis and atherothrombosis--focus on diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009,23(3),291-303","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.5772\/1062","author":"Gaxiola E.","year":"2012","unstructured":"Gaxiola E.;  Traditional and novel risk factors in atherothrombosis 2012","journal-title":"Traditional and novel risk factors in atherothrombosis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.ehj.2004.03.011","volume":"25","author":"Viles-Gonzalez J.F.","year":"2004","unstructured":"Viles-Gonzalez J.F.; Fuster V.; Badimon J.J.; Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004,25(14),1197-1207","journal-title":"Eur Heart J"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jacc.2005.03.074","volume":"46","author":"Fuster V.","year":"2005","unstructured":"Fuster V.; Moreno P.R.; Fayad Z.A.; Corti R.; Badimon J.J.; Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005,46(6),937-954","journal-title":"J Am Coll Cardiol"},{"key":"ref=8","first-page":"337","author":"Betsy B.","year":"2003","unstructured":"Betsy B.;  Stroke in Young Adults; Martin A Samuels; Steven K Feske, Ed 2003,337-352","journal-title":"Stroke in Young Adults; Martin A Samuels; Steven K Feske, Ed"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jacc.2005.03.075","volume":"46","author":"Fuster V.","year":"2005","unstructured":"Fuster V.; Fayad Z.A.; Moreno P.R.; Poon M.; Corti R.; Badimon J.J.; Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic\/magnetic resonance imaging. J Am Coll Cardiol 2005,46(7),1209-1218","journal-title":"J Am Coll Cardiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.coph.2012.12.005","volume":"13","author":"Jacomella V.","year":"2013","unstructured":"Jacomella V.; Corti N.; Husmann M.; Novel anticoagulants in the therapy of peripheral arterial and coronary artery disease. Curr Opin Pharmacol 2013,13(2),294-300","journal-title":"Curr Opin Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/joim.12406","volume":"278","author":"Hansson G.K.","year":"2015","unstructured":"Hansson G.K.; Libby P.; Tabas I.; Inflammation and plaque vulnerability. J Intern Med 2015,278(5),483-493","journal-title":"J Intern Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1111\/j.1538-7836.2006.02202.x","volume":"4","author":"Yeh E.T.H.","year":"2006","unstructured":"Yeh E.T.H.; Khan B.V.; The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J Thromb Haemost 2006,4(11),2308-2316","journal-title":"J Thromb Haemost"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.atherosclerosis.2019.03.006","volume":"284","author":"Ouweneel A.B.","year":"2019","unstructured":"Ouweneel A.B.; Verwilligen R.A.F.; Van Eck M.; Vulnerable plaque and vulnerable blood: Two critical factors for spontaneous atherothrombosis in mouse models. Atherosclerosis 2019,284,160-164","journal-title":"Atherosclerosis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1161\/01.CIR.94.8.2013","volume":"94","author":"Davies M.J.","year":"1996","unstructured":"Davies M.J.; Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996,94(8),2013-2020","journal-title":"Circulation"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1331\/154434504322904569","volume":"44","author":"Munger M.A.","year":"2004","unstructured":"Munger M.A.; Hawkins D.W.; Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc (2003) 2004,44(2)(Suppl. 1),S5-S12","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.5551\/jat.RV17022","volume":"25","author":"Asada Y.","year":"2018","unstructured":"Asada Y.; Yamashita A.; Sato Y.; Hatakeyama K.; Thrombus formation and propagation in the onset of cardiovascular events. J Atheroscler Thromb 2018,25(8),653-664","journal-title":"J Atheroscler Thromb"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4065\/82.5.583","volume":"82","author":"Kikano G.E.","year":"2007","unstructured":"Kikano G.E.; Brown M.T.; Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. Mayo Clin Proc 2007,82(5),583-593","journal-title":"Mayo Clin Proc"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","volume":"114","author":"Bentzon J.F.","year":"2014","unstructured":"Bentzon J.F.; Otsuka F.; Virmani R.; Falk E.; Mechanisms of plaque formation and rupture. Circ Res 2014,114(12),1852-1866","journal-title":"Circ Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/pin.12921","volume":"70","author":"Asada Y.","year":"2020","unstructured":"Asada Y.; Yamashita A.; Sato Y.; Hatakeyama K.; Pathophysiology of atherothrombosis: Mechanisms of thrombus formation on disrupted atherosclerotic plaques. Pathol Int 2020,70(6),309-322","journal-title":"Pathol Int"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"Libby P.","year":"2019","unstructured":"Libby P.; Buring J.E.; Badimon L.; Hansson G.K.; Deanfield J.; Bittencourt M.S.; Tokg\u00f6zo\u011flu L.; Lewis E.F.; Atherosclerosis. Nat Rev Dis Primers 2019,5(1),56","journal-title":"Nat Rev Dis Primers"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1157\/13119995","volume":"61","author":"Badimon L.","year":"2008","unstructured":"Badimon L.; Vilahur G.; Coronary atherothrombotic disease: progress in antiplatelet therapy. Rev Esp Cardiol 2008,61(5),501-513","journal-title":"Rev Esp Cardiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJM199201303260506","volume":"326","author":"Fuster V.","year":"1992","unstructured":"Fuster V.; Badimon L.; Badimon J.J.; Chesebro J.H.; Chesebro J.H.; The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992,326(5),310-318","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0021-9150(98)00107-5","volume":"139","author":"Camejo G.","year":"1998","unstructured":"Camejo G.; Hurt-Camejo E.; Wiklund O.; Bondjers G.; Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998,139(2),205-222","journal-title":"Atherosclerosis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1126\/science.1990440","volume":"251","author":"Cybulsky M.I.","year":"1991","unstructured":"Cybulsky M.I.; Gimbrone M.A.; Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991,251(4995),788-791","journal-title":"Science"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0021-9150(99)00479-7","volume":"149","author":"Zaman A.G.","year":"2000","unstructured":"Zaman A.G.; Helft G.; Worthley S.G.; Badimon J.J.; The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000,149(2),251-266","journal-title":"Atherosclerosis"},{"key":"ref=26","first-page":"927","volume":"5","author":"Rafieian-Kopaei M.","year":"2014","unstructured":"Rafieian-Kopaei M.; Setorki M.; Doudi M.; Baradaran A.; Nasri H.; Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014,5(8),927-946","journal-title":"Int J Prev Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"Ross R.","year":"1999","unstructured":"Ross R.; Atherosclerosis--an inflammatory disease. N Engl J Med 1999,340(2),115-126","journal-title":"N Engl J Med"},{"key":"ref=28","first-page":"665","volume":"140","author":"Poston R.N.","year":"1992","unstructured":"Poston R.N.; Haskard D.O.; Coucher J.R.; Gall N.P.; Johnson-Tidey R.R.; Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 1992,140(3),665-673","journal-title":"Am J Pathol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1161\/hq1201.100220","volume":"21","author":"Hansson G.K.","year":"2001","unstructured":"Hansson G.K.; Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001,21(12),1876-1890","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=30","first-page":"251","volume":"147","author":"Geng Y-J.","year":"1995","unstructured":"Geng Y-J.; Libby P.; Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol 1995,147(2),251-266","journal-title":"Am J Pathol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/2048872612441582","volume":"1","author":"Badimon L.","year":"2012","unstructured":"Badimon L.; Padr\u00f3 T.; Vilahur G.; Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care 2012,1(1),60-74","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1161\/01.RES.77.5.863","volume":"77","author":"Dollery C.M.","year":"1995","unstructured":"Dollery C.M.; McEwan J.R.; Henney A.M.; Matrix metalloproteinases and cardiovascular disease. Circ Res 1995,77(5),863-868","journal-title":"Circ Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/01.CIR.92.8.2029","volume":"92","author":"Demer L.L.","year":"1995","unstructured":"Demer L.L.; A skeleton in the atherosclerosis closet. Circulation 1995,92(8),2029-2032","journal-title":"Circulation"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/01.CIR.104.3.365","volume":"104","author":"Libby P.","year":"2001","unstructured":"Libby P.; Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001,104(3),365-372","journal-title":"Circulation"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1093\/eurheartj\/ehx143","volume":"38","author":"Nilsson J.","year":"2017","unstructured":"Nilsson J.; Atherosclerotic plaque vulnerability in the statin era. Eur Heart J 2017,38(21),1638-1644","journal-title":"Eur Heart J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/01.CIR.93.7.1354","volume":"93","author":"Farb A.","year":"1996","unstructured":"Farb A.; Burke A.P.; Tang A.L.; Liang T.Y.; Mannan P.; Smialek J.; Virmani R.; Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996,93(7),1354-1363","journal-title":"Circulation"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.282.21.2035","volume":"282","author":"Malek A.M.","year":"1999","unstructured":"Malek A.M.; Alper S.L.; Izumo S.; Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999,282(21),2035-2042","journal-title":"JAMA"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"17A","DOI":"10.1016\/S0002-9149(02)03146-6","volume":"91","author":"Corti R.","year":"2003","unstructured":"Corti R.; Fuster V.; New understanding, diagnosis, and prognosis of atherothrombosis and the role of imaging. Am J Cardiol 2003,91(3A),17A-26A","journal-title":"Am J Cardiol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e003553","DOI":"10.1161\/JAHA.116.003553","volume":"5","author":"Ten Cate H.","year":"2016","unstructured":"Ten Cate H.; Hemker H.C.; Thrombin generation and atherothrombosis: What does the evidence indicate? J Am Heart Assoc 2016,5(8),e003553","journal-title":"J Am Heart Assoc"},{"key":"ref=40","first-page":"155","volume":"4","author":"Christos D.","year":"2017","unstructured":"Christos D.; George R.; Xanthi R.; Sotiria P.; Varvara M.; Christos H.; A cross sectional study on knowledge, atitudes, and practices of Greek cardiologists towards screening recommendations for cardiovascular diseases. Int Res J Pub Environ Health 2017,4(7),155-169","journal-title":"Int Res J Pub Environ Health"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"Benjamin E.J.","year":"2017","unstructured":"Benjamin E.J.; Blaha M.J.; Chiuve S.E.; Cushman M.; Das S.R.; Deo R.; de Ferranti S.D.; Floyd J.; Fornage M.; Gillespie C.; Isasi C.R.; Jim\u00e9nez M.C.; Jordan L.C.; Judd S.E.; Lackland D.; Lichtman J.H.; Lisabeth L.; Liu S.; Longenecker C.T.; Mackey R.H.; Matsushita K.; Mozaffarian D.; Mussolino M.E.; Nasir K.; Neumar R.W.; Palaniappan L.; Pandey D.K.; Thiagarajan R.R.; Reeves M.J.; Ritchey M.; Rodriguez C.J.; Roth G.A.; Rosamond W.D.; Sasson C.; Towfighi A.; Tsao C.W.; Turner M.B.; Virani S.S.; Voeks J.H.; Willey J.Z.; Wilkins J.T.; Wu J.H.; Alger H.M.; Wong S.S.; Muntner P.; American heart association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2017 update: a report from the american heart association. Circulation 2017,135(10),e146-e603","journal-title":"Circulation"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1365-2796.2008.01947.x","volume":"263","author":"Thim T.","year":"2008","unstructured":"Thim T.; Hagensen M.K.; Bentzon J.F.; Falk E.; From vulnerable plaque to atherothrombosis. J Intern Med 2008,263(5),506-516","journal-title":"J Intern Med"},{"key":"ref=43","first-page":"109","volume":"60","year":"2011","unstructured":"Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200. MMWR Morb Mortal Wkly Rep Centers for Disease Control and Prevention (CDC)2011,60(4),109-114","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","volume":"380","author":"Lim S.S.","year":"2012","unstructured":"Lim S.S.; Vos T.; Flaxman A.D.; Danaei G.; Shibuya K.; Adair-Rohani H.; Amann M.; Anderson H.R.; Andrews K.G.; Aryee M.; A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012,380(9859),2224-2260","journal-title":"Lancet"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1001\/jama.2012.70830","volume":"308","author":"Webber B.J.","year":"2012","unstructured":"Webber B.J.; Seguin P.G.; Burnett D.G.; Clark L.L.; Otto J.L.; Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011. JAMA 2012,308(24),2577-2583","journal-title":"JAMA"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1161\/CIRCULATIONAHA.111.070722","volume":"125","author":"Huffman M.D.","year":"2012","unstructured":"Huffman M.D.; Capewell S.; Ning H.; Shay C.M.; Ford E.S.; Lloyd-Jones D.M.; Cardiovascular health behavior and health factor changes (1988-2008) and projections to 2020: results from the National Health and Nutrition Examination Surveys. Circulation 2012,125(21),2595-2602","journal-title":"Circulation"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e0229438","DOI":"10.1371\/journal.pone.0229438","volume":"15","author":"Luhar S.","year":"2020","unstructured":"Luhar S.; Tim\u00e6us I.M.; Jones R.; Cunningham S.; Patel S.A.; Kinra S.; Clarke L.; Houben R.; Forecasting the prevalence of overweight and obesity in India to 2040. PLoS One 2020,15(2),e0229438","journal-title":"PLoS One"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMsa1211127","volume":"368","author":"Thun M.J.","year":"2013","unstructured":"Thun M.J.; Carter B.D.; Feskanich D.; Freedman N.D.; Prentice R.; Lopez A.D.; Hartge P.; Gapstur S.M.; 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013,368(4),351-364","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jacc.2012.04.045","volume":"60","author":"Sanz J.","year":"2012","unstructured":"Sanz J.; Moreno P.R.; Fuster V.; The year in atherothrombosis. J Am Coll Cardiol 2012,60(10),932-942","journal-title":"J Am Coll Cardiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi M.","year":"2016","unstructured":"Roffi M.; Patrono C.; Collet J-P.; Mueller C.; Valgimigli M.; Andreotti F.; Bax J.J.; Borger M.A.; Brotons C.; Chew D.P.; Gencer B.; Hasenfuss G.; Kjeldsen K.; Lancellotti P.; Landmesser U.; Mehilli J.; Mukherjee D.; Storey R.F.; Windecker S.; 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation of the European Society of Cardiology (ESC). Eur Heart J ESC scientific document group2016,37(3),267-315","journal-title":"Eur Heart J"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"Lozano R.","year":"2012","unstructured":"Lozano R.; Naghavi M.; Foreman K.; Lim S.; Shibuya K.; Aboyans V.; Abraham J.; Adair T.; Aggarwal R.; Ahn S.Y.; Alvarado M.; Anderson H.R.; Anderson L.M.; Andrews K.G.; Atkinson C.; Baddour L.M.; Barker-Collo S.; Bartels D.H.; Bell M.L.; Benjamin E.J.; Bennett D.; Bhalla K.; Bikbov B.; Bin Abdulhak A.; Birbeck G.; Blyth F.; Bolliger I.; Boufous S.; Bucello C.; Burch M.; Burney P.; Carapetis J.; Chen H.; Chou D.; Chugh S.S.; Coffeng L.E.; Colan S.D.; Colquhoun S.; Colson K.E.; Condon J.; Connor M.D.; Cooper L.T.; Corriere M.; Cortinovis M.; de Vaccaro K.C.; Couser W.; Cowie B.C.; Criqui M.H.; Cross M.; Dabhadkar K.C.; Dahodwala N.; De Leo D.; Degenhardt L.; Delossantos A.; Denenberg J.; Des Jarlais D.C.; Dharmaratne S.D.; Dorsey E.R.; Driscoll T.; Duber H.; Ebel B.; Erwin P.J.; Espindola P.; Ezzati M.; Feigin V.; Flaxman A.D.; Forouzanfar M.H.; Fowkes F.G.R.; Franklin R.; Fransen M.; Freeman M.K.; Gabriel S.E.; Gakidou E.; Gaspari F.; Gillum R.F.; Gonzalez-Medina D.; Halasa Y.A.; Haring D.; Harrison J.E.; Havmoeller R.; Hay R.J.; Hoen B.; Hotez P.J.; Hoy D.; Jacobsen K.H.; James S.L.; Jasrasaria R.; Jayaraman S.; Johns N.; Karthikeyan G.; Kassebaum N.; Keren A.; Khoo J-P.; Knowlton L.M.; Kobusingye O.; Koranteng A.; Krishnamurthi R.; Lipnick M.; Lipshultz S.E.; Ohno S.L.; Mabweijano J.; MacIntyre M.F.; Mallinger L.; March L.; Marks G.B.; Marks R.; Matsumori A.; Matzopoulos R.; Mayosi B.M.; McAnulty J.H.; McDermott M.M.; McGrath J.; Mensah G.A.; Merriman T.R.; Michaud C.; Miller M.; Miller T.R.; Mock C.; Mocumbi A.O.; Mokdad A.A.; Moran A.; Mulholland K.; Nair M.N.; Naldi L.; Narayan K.M.V.; Nasseri K.; Norman P.; O\u2019Donnell M.; Omer S.B.; Ortblad K.; Osborne R.; Ozgediz D.; Pahari B.; Pandian J.D.; Rivero A.P.; Padilla R.P.; Perez-Ruiz F.; Perico N.; Phillips D.; Pierce K.; Pope C.A.; Porrini E.; Pourmalek F.; Raju M.; Ranganathan D.; Rehm J.T.; Rein D.B.; Remuzzi G.; Rivara F.P.; Roberts T.; De Le\u00f3n F.R.; Rosenfeld L.C.; Rushton L.; Sacco R.L.; Salomon J.A.; Sampson U.; Sanman E.; Schwebel D.C.; Segui-Gomez M.; Shepard D.S.; Singh D.; Singleton J.; Sliwa K.; Smith E.; Steer A.; Taylor J.A.; Thomas B.; Tleyjeh I.M.; Towbin J.A.; Truelsen T.; Undurraga E.A.; Venketasubramanian N.; Vijayakumar L.; Vos T.; Wagner G.R.; Wang M.; Wang W.; Watt K.; Weinstock M.A.; Weintraub R.; Wilkinson J.D.; Woolf A.D.; Wulf S.; Yeh P.H.; Yip P.; Zabetian A.; Zheng Z.J.; Lopez A.D.; Murray C.J.; AlMazroa M.A.; Memish Z.A.; Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012,380(9859),2095-2128","journal-title":"Lancet"},{"key":"ref=52","author":"Jha P.","year":"2012","unstructured":"Jha P.; Nugent R.; Verguet S.; Bloom D.; Hum R.; Chronic disease prevention and control. Copenhagen Consensus 2012 Challenge Paper 2012","journal-title":"Copenhagen Consensus 2012 Challenge Paper"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/CIRCULATIONAHA.111.060681","volume":"125","author":"Liu K.","year":"2012","unstructured":"Liu K.; Daviglus M.L.; Loria C.M.; Colangelo L.A.; Spring B.; Moller A.C.; Lloyd-Jones D.M.; Healthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study. Circulation 2012,125(8),996-1004","journal-title":"Circulation"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"Catapano A.L.","year":"2016","unstructured":"Catapano A.L.; Graham I.; De Backer G.; Wiklund O.; Chapman M.J.; Drexel H.; Hoes A.W.; Jennings C.S.; Landmesser U.; Pedersen T.R.; Reiner \u017d.; Riccardi G.; Taskinen M.R.; Tokgozoglu L.; Verschuren W.M.M.; Vlachopoulos C.; Wood D.A.; Zamorano J.L.; Cooney M.T.; 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J ESC Scientific Document Group2016,37(39),2999-3058","journal-title":"Eur Heart J"},{"key":"ref=55","volume":"6","author":"Dziedzic E.","year":"2018","unstructured":"Dziedzic E.; Machowski M.; Oleszczak-Kostyra M.; D\u0105browski M.J.; Atherothrombosis as a Leading Cause of Acute Coronary Syndromes and Stroke: The Main Killers in Developed Countries Atherosclerosis - Yesterday, Today and Tomorrow; Luigi Gianturco, Ed 2018,6 https:\/\/www.intechopen.com\/books\/atherosclerosis-yesterday-today-and-tomorrow\/atherothrombosis-as-a-leading-cause-of-acute-coronary-syndromes-and-stroke-the-main-killers-in-devel","journal-title":"Atherosclerosis - Yesterday, Today and Tomorrow; Luigi Gianturco, Ed"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1161\/CIRCULATIONAHA.112.121301","volume":"126","author":"Tan C.E.","year":"2012","unstructured":"Tan C.E.; Glantz S.A.; Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: a meta-analysis. Circulation 2012,126(18),2177-2183","journal-title":"Circulation"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ahj.2011.10.014","volume":"163","author":"Suzuki T.","year":"2012","unstructured":"Suzuki T.; Kohro T.; Hayashi D.; Yamazaki T.; Nagai R.; Frequency and impact of lifestyle modification in patients with coronary artery disease: the Japanese Coronary Artery Disease (JCAD) study. Am Heart J 2012,163(2),268-273","journal-title":"Am Heart J"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11883-020-0819-1","volume":"22","author":"Biondi-Zoccai G.","year":"2020","unstructured":"Biondi-Zoccai G.; Garmendia C.M.; Abbate A.; Giordano A.; Frati G.; Sciarretta S.; Antonazzo B.; Versaci F.; Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents. Curr Atheroscler Rep 2020,22(1),4","journal-title":"Curr Atheroscler Rep"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/FJC.0000000000000591","volume":"72","author":"Buckley L.F.","year":"2018","unstructured":"Buckley L.F.; Carbone S.; Trankle C.R.; Canada J.M.; Erdle C.O.; Regan J.A.; Viscusi M.M.; Kadariya D.; Billingsley H.; Arena R.; Abbate A.; Van Tassell B.W.; Effect of interleukin-1 blockade on left ventricular systolic performance and work: a post hoc pooled analysis of 2 clinical trials. J Cardiovasc Pharmacol 2018,72(1),68-70","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/clc.23246","volume":"42","author":"Zheng Z.H.","year":"2019","unstructured":"Zheng Z.H.; Zeng X.; Nie X.Y.; Cheng Y.J.; Liu J.; Lin X.X.; Yao H.; Ji C.C.; Chen X.M.; Jun F.; Wu S.H.; Interleukin-1 blockade treatment decreasing cardiovascular risk. Clin Cardiol 2019,42(10),942-951","journal-title":"Clin Cardiol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","volume":"61","author":"Savarese G.","year":"2013","unstructured":"Savarese G.; Costanzo P.; Cleland J.G.F.; Vassallo E.; Ruggiero D.; Rosano G.; Perrone-Filardi P.; A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013,61(2),131-142","journal-title":"J Am Coll Cardiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/eurheartj\/ehr400","volume":"33","author":"McAlister F.A.","year":"2012","unstructured":"McAlister F.A.; Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J Renin Angiotension System Modulator Meta-Analysis Investigators2012,33(4),505-514","journal-title":"Eur Heart J"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"Gerstein H.C.","year":"2012","unstructured":"Gerstein H.C.; Bosch J.; Dagenais G.R.; D\u00edaz R.; Jung H.; Maggioni A.P.; Pogue J.; Probstfield J.; Ramachandran A.; Riddle M.C.; Ryd\u00e9n L.E.; Yusuf S.; Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med ORIGIN Trial Investigators2012,367(4),319-328","journal-title":"N Engl J Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","year":"2002","unstructured":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002,324(7329),71-86","journal-title":"BMJ"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-2261-14-100","volume":"14","author":"Thim T.","year":"2014","unstructured":"Thim T.; Johansen M.B.; Chisholm G.E.; Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord 2014,14(1),100","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1093\/eurheartj\/ehs202","volume":"33","author":"Charlot M.","year":"2012","unstructured":"Charlot M.; Nielsen L.H.; Lindhardsen J.; Ahlehoff O.; Olsen A-M.S.; Hansen M.L.; Hansen P.R.; Madsen J.K.; K\u00f8ber L.; Gislason G.H.; Torp-Pedersen C.; Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. Eur Heart J 2012,33(20),2527-2534","journal-title":"Eur Heart J"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"Dewilde W.J.","year":"2013","unstructured":"Dewilde W.J.; Oirbans T.; Verheugt F.W.; Kelder J.C.; De Smet B.J.; Herrman J-P.; Adriaenssens T.; Vrolix M.; Heestermans A.A.; Vis M.M.; Tijsen J.G.; van \u2019t Hof A.W.; ten Berg J.M.; Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet WOEST study investigators2013,381(9872),1107-1115","journal-title":"Lancet"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1001\/jama.2012.17312","volume":"308","author":"Gurbel P.A.","year":"2012","unstructured":"Gurbel P.A.; Erlinge D.; Ohman E.M.; Neely B.; Neely M.; Goodman S.G.; Platelet function during extended prasugrel and clopidogrel therapy for patients with acs treated without revascularization. JAMA 2012,308(17),E1-E10","journal-title":"JAMA"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","volume":"367","author":"Collet J-P.","year":"2012","unstructured":"Collet J-P.; Cuisset T.; Rang\u00e9 G.; Cayla G.; Elhadad S.; Pouillot C.; Henry P.; Motreff P.; Carri\u00e9 D.; Boueri Z.; Belle L.; Van Belle E.; Rousseau H.; Aubry P.; Mons\u00e9gu J.; Sabouret P.; O\u2019Connor S.A.; Abtan J.; Kerneis M.; Saint-Etienne C.; Barth\u00e9l\u00e9my O.; Beygui F.; Silvain J.; Vicaut E.; Montalescot G.; Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med ARCTIC Investigators2012,367(22),2100-2109","journal-title":"N Engl J Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1016\/B978-0-12-386456-7.06206-7","author":"Marshall A.H.","year":"2014","unstructured":"Marshall A.H.; Wang Y.; Reheman A.; Chen P.; Zhu G.; Ni H.;  Linda M McManus, Richard N Mitchell, Ed 2014,3101-3114","journal-title":"Linda M McManus, Richard N Mitchell, Ed"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.tmrv.2014.11.006","volume":"29","author":"McFadyen J.D.","year":"2015","unstructured":"McFadyen J.D.; Kaplan Z.S.; Platelets are not just for clots. Transfus Med Rev 2015,29(2),110-119","journal-title":"Transfus Med Rev"},{"key":"ref=72","volume":"5","author":"Twomey L.","year":"2018","unstructured":"Twomey L.; Wallace R.G.; Cummins M.; Degryse B.; Sheridan S.; Harrison M.; Platelets: from formation to function; homeostasis - an integrated vision fernanda lasakosvitsch, Sergio Dos Anjos Garnes, Ed 2018,5 https:\/\/www.intechopen.com\/books\/homeostasis-an-integrated-vision\/platelets-from-formation-to-function","journal-title":"fernanda lasakosvitsch, Sergio Dos Anjos Garnes, Ed"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"125","DOI":"10.29074\/ascls.28.2.125","volume":"28","author":"Fritsma G.A.","year":"2015","unstructured":"Fritsma G.A.; Platelet structure and function. Clin Lab Sci 2015,28(2),125-131","journal-title":"Clin Lab Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nri2956","volume":"11","author":"Semple J.W.","year":"2011","unstructured":"Semple J.W.; Italiano J.E.; Freedman J.; Platelets and the immune continuum. Nat Rev Immunol 2011,11(4),264-274","journal-title":"Nat Rev Immunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1083\/jcb.201304054","volume":"201","author":"Machlus K.R.","year":"2013","unstructured":"Machlus K.R.; Italiano J.E.; The incredible journey: From megakaryocyte development to platelet formation. J Cell Biol 2013,201(6),785-796","journal-title":"J Cell Biol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4065\/81.1.59","volume":"81","author":"Vorchheimer D.A.","year":"2006","unstructured":"Vorchheimer D.A.; Becker R.; Platelets in atherothrombosis. Mayo Clin Proc 2006,81(1),59-68","journal-title":"Mayo Clin Proc"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cnur.2015.10.004","volume":"51","author":"Shifrin M.M.","year":"2016","unstructured":"Shifrin M.M.; Widmar S.B.; Platelet Inhibitors. Nurs Clin North Am 2016,51(1),29-43","journal-title":"Nurs Clin North Am"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/313842","author":"Azeredo E","year":"2015","unstructured":"Azeredo E; Thrombocytopenia in dengue: interrelationship between virus and the imbalance between coagulation and fibrinolysis and inflammatory mediators. Mediat Inflamm 2015,1-16","journal-title":"Mediat Inflamm"},{"key":"ref=79","author":"Sharda A.","year":"2018","unstructured":"Sharda A.; Flaumenhaft R.; The life cycle of platelet granules. F1000 Research 2018","journal-title":"F1000 Research"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41569-019-0233-y","volume":"17","author":"Fox K.A.A.","year":"2020","unstructured":"Fox K.A.A.; Metra M.; Morais J.; Atar D.; The myth of \u2018stable\u2019 coronary artery disease. Nat Rev Cardiol 2020,17(1),9-21","journal-title":"Nat Rev Cardiol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/00000542-200403000-00036","volume":"100","author":"Roberts H.R.","year":"2004","unstructured":"Roberts H.R.; Monroe D.M.; Escobar M.A.; Current concepts of hemostasis: implications for therapy. Anesthesiology 2004,100(3),722-730","journal-title":"Anesthesiology"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.arr.2018.09.004","volume":"48","author":"Simeone P.","year":"2018","unstructured":"Simeone P.; Boccatonda A.; Liani R.; Santilli F.; Significance of urinary 11-dehydro-thromboxane B in age-related diseases: Focus on atherothrombosis. Ageing Res Rev 2018,48(48),51-78","journal-title":"Ageing Res Rev"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1152\/physiol.00020.2016","volume":"32","author":"Estevez B.","year":"2017","unstructured":"Estevez B.; Du X.; New concepts and mechanisms of platelet activation signaling. Physiology (Bethesda) 2017,32(2),162-177","journal-title":"Physiology (Bethesda)"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0735-1097(97)00510-X","volume":"31","author":"Furman M.I.","year":"1998","unstructured":"Furman M.I.; Benoit S.E.; Barnard M.R.; Valeri C.R.; Borbone M.L.; Becker R.C.; Hechtman H.B.; Michelson A.D.; Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998,31(2),352-358","journal-title":"J Am Coll Cardiol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jacc.2009.11.051","volume":"55","author":"Reininger A.J.","year":"2010","unstructured":"Reininger A.J.; Bernlochner I.; Penz S.M.; Ravanat C.; Smethurst P.; Farndale R.W.; Gachet C.; Brandl R.; Siess W.; A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 2010,55(11),1147-1158","journal-title":"J Am Coll Cardiol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/01.RES.0000070111.98158.6C","volume":"92","author":"Inwald D.P.","year":"2003","unstructured":"Inwald D.P.; McDowall A.; Peters M.J.; Callard R.E.; Klein N.J.; CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003,92(9),1041-1048","journal-title":"Circ Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood.V98.4.1047","volume":"98","author":"Henn V.","year":"2001","unstructured":"Henn V.; Steinbach S.; B\u00fcchner K.; Presek P.; Kroczek R.A.; The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001,98(4),1047-1054","journal-title":"Blood"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1194\/jlr.R800042-JLR200","volume":"50","author":"Rouzer C.A.","year":"2009","unstructured":"Rouzer C.A.; Marnett L.J.; Cyclooxygenases: structural and functional insights. J Lipid Res 2009,50(Suppl.),S29-S34","journal-title":"J Lipid Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2165\/11536000-000000000-00000","volume":"70","author":"Coccheri S.","year":"2010","unstructured":"Coccheri S.; Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors. Drugs 2010,70(7),887-908","journal-title":"Drugs"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/1074248419899314","volume":"25","author":"Tscharre M.","year":"2020","unstructured":"Tscharre M.; Michelson A.D.; Gremmel T.; Novel Antiplatelet Agents in Cardiovascular Disease. J Cardiovasc Pharmacol Ther 2020,25(3),191-200","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","volume":"32","author":"Patrono C.","year":"2011","unstructured":"Patrono C.; Andreotti F.; Arnesen H.; Badimon L.; Baigent C.; Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011,32(23),2922-2932","journal-title":"Eur Heart J"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","volume":"70","author":"Patrono C.","year":"2017","unstructured":"Patrono C.; Morais J.; Baigent C.; Collet J-P.; Fitzgerald D.; Halvorsen S.; Rocca B.; Siegbahn A.; Storey R.F.; Vilahur G.; Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol 2017,70(14),1760-1776","journal-title":"J Am Coll Cardiol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","volume":"72","author":"Warner T.D.","year":"2011","unstructured":"Warner T.D.; Nylander S.; Whatling C.; Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol 2011,72(4),619-633","journal-title":"Br J Clin Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"Bhala N.","year":"2013","unstructured":"Bhala N.; Emberson J.; Merhi A.; Abramson S.; Arber N.; Baron J.A.; Bombardier C.; Cannon C.; Farkouh M.E.; FitzGerald G.A.; Goss P.; Halls H.; Hawk E.; Hawkey C.; Hennekens C.; Hochberg M.; Holland L.E.; Kearney P.M.; Laine L.; Lanas A.; Lance P.; Laupacis A.; Oates J.; Patrono C.; Schnitzer T.J.; Solomon S.; Tugwell P.; Wilson K.; Wittes J.; Baigent C.; Adelowo O.; Aisen P.; Al-Quorain A.; Altman R.; Bakris G.; Baumgartner H.; Bresee C.; Carducci M.; Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration2013,382(9894),769-779","journal-title":"Lancet"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccl.2010.10.001","volume":"29","author":"Kolandaivelu K.","year":"2011","unstructured":"Kolandaivelu K.; Bhatt D.L.; Antiplatelet therapy in coronary heart disease prevention. Cardiol Clin 2011,29(1),71-85","journal-title":"Cardiol Clin"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/j.clinthera.2014.10.012","volume":"36","author":"Patrono C.","year":"2014","unstructured":"Patrono C.; Role of clinical pharmacology in the development of antiplatelet drugs. Clin Ther 2014,36(12),2096-2111","journal-title":"Clin Ther"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.hoc.2004.09.004","volume":"19","author":"Messmore H.L.","year":"2005","unstructured":"Messmore H.L.; Jeske W.P.; Wehrmacher W.; Coyne E.; Mobarhan S.; Cho L.; Leya F.S.; Moran J.F.; Antiplatelet agents: current drugs and future trends. Hematol Oncol Clin North Am 2005,19(1),87-117, vi","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3810\/pgm.2013.07.2682","volume":"125","author":"Norgard N.B.","year":"2013","unstructured":"Norgard N.B.; Dinicolantonio J.J.; Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med 2013,125(4),91-102","journal-title":"Postgrad Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ihj.2015.11.029","volume":"68","author":"Kaul U.","year":"2016","unstructured":"Kaul U.; Mohan J.C.; Choice of antithrombotics in acute coronary syndrome - A balance of efficacy versus safety. Indian Heart J 2016,68(4),441-444","journal-title":"Indian Heart J"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","year":"1996","unstructured":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996,348(9038),1329-1339","journal-title":"Lancet"},{"key":"ref=101","first-page":"1","author":"Gremmel T.","year":"2018","unstructured":"Gremmel T.; Michelson A.D.; Frelinger A.L.; Bhatt D.L.; Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018,1-11","journal-title":"Res Pract Thromb Haemost"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ejim.2009.09.005","volume":"20","author":"Franchini M.","year":"2009","unstructured":"Franchini M.; Mannucci P.M.; New antiplatelet agents: why they are needed. Eur J Intern Med 2009,20(8),733-738","journal-title":"Eur J Intern Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ahj.2010.10.043","volume":"161","author":"White H.D.","year":"2011","unstructured":"White H.D.; Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. Am Heart J 2011,161(3),450-461","journal-title":"Am Heart J"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1538-7836.2009.03382.x","volume":"7","author":"Cattaneo M.","year":"2009","unstructured":"Cattaneo M.; New P2Y12 blockers. J Thromb Haemost 2009,7(Suppl. 1),262-265","journal-title":"J Thromb Haemost"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"Husted S.","year":"2006","unstructured":"Husted S.; Emanuelsson H.; Heptinstall S.; Sandset P.M.; Wickens M.; Peters G.; Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006,27(9),1038-1047","journal-title":"Eur Heart J"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ahj.2010.06.007","volume":"160","author":"Gaglia M.A.","year":"2010","unstructured":"Gaglia M.A.; Manoukian S.V.; Waksman R.; Novel antiplatelet therapy. Am Heart J 2010,160(4),595-604","journal-title":"Am Heart J"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/0091270009344986","volume":"50","author":"Akers W.S.","year":"2010","unstructured":"Akers W.S.; Oh J.J.; Oestreich J.H.; Ferraris S.; Wethington M.; Steinhubl S.R.; Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y receptor antagonist. J Clin Pharmacol 2010,50(1),27-35","journal-title":"J Clin Pharmacol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","volume":"121","author":"Steinhubl S.R.","year":"2008","unstructured":"Steinhubl S.R.; Oh J.J.; Oestreich J.H.; Ferraris S.; Charnigo R.; Akers W.S.; Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008,121(4),527-534","journal-title":"Thromb Res"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1160\/TH13-11-0915","volume":"112","author":"Adamski P.","year":"2014","unstructured":"Adamski P.; Kozi\u0144ski M.; Ostrowska M.; Fabiszak T.; Navarese E.P.; Paciorek P.; Grze\u015bk G.; Kubica J.; Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost 2014,112(2),224-242","journal-title":"Thromb Haemost"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s10554-011-9910-6","volume":"28","author":"Takeda M.","year":"2012","unstructured":"Takeda M.; Yamashita T.; Shinohara M.; Sasaki N.; Tawa H.; Nakajima K.; Momose A.; Hirata K.; Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging. Int J Cardiovasc Imaging 2012,28(5),1181-1191","journal-title":"Int J Cardiovasc Imaging"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.atherosclerosis.2006.12.009","volume":"196","author":"Warnholtz A.","year":"2008","unstructured":"Warnholtz A.; Ostad M.A.; Velich N.; Trautmann C.; Schinzel R.; Walter U.; Munzel T.; A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008,196(2),689-695","journal-title":"Atherosclerosis"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1160\/TH11-12-0867","volume":"107","author":"Totani L.","year":"2012","unstructured":"Totani L.; Dell\u2019Elba G.; Martelli N.; Di Santo A.; Piccoli A.; Amore C.; Evangelista V.; Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thromb Haemost 2012,107(6),1130-1140","journal-title":"Thromb Haemost"},{"key":"ref=113","first-page":"1","author":"Parker W.A.E.","year":"2018","unstructured":"Parker W.A.E.; Eriksson N.; Becker R.C.; Voora D.; Akerblom A.; Himmelmann A.; James S.K.; Wallentin L.; Storey R.F.; Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets 2018,1-10","journal-title":"Platelets"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1074248413511693","volume":"19","author":"Armstrong D.","year":"2014","unstructured":"Armstrong D.; Summers C.; Ewart L.; Nylander S.; Sidaway J.E.; van Giezen J.J.; Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 2014,19(2),209-219","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/ijms21041391","volume":"21","author":"Mansour A.","year":"2020","unstructured":"Mansour A.; Bachelot-Loza C.; Nesseler N.; Gaussem P.; Gouin-Thibault I.; P2Y inhibition beyond thrombosis: effects on inflammation. Int J Mol Sci 2020,21(4),1391","journal-title":"Int J Mol Sci"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1074248411410883","volume":"17","author":"van Giezen J.J.","year":"2012","unstructured":"van Giezen J.J.; Sidaway J.; Glaves P.; Kirk I.; Bj\u00f6rkman J.A.; Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012,17(2),164-172","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","volume":"63","author":"Bonello L.","year":"2014","unstructured":"Bonello L.; Laine M.; Kipson N.; Mancini J.; Helal O.; Fromonot J.; Gariboldi V.; Condo J.; Thuny F.; Frere C.; Camoin-Jau L.; Paganelli F.; Dignat-George F.; Guieu R.; Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014,63(9),872-877","journal-title":"J Am Coll Cardiol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1161\/ATVBAHA.110.219501","volume":"31","author":"Iy\u00fa D.","year":"2011","unstructured":"Iy\u00fa D.; Glenn J.R.; White A.E.; Fox S.C.; Heptinstall S.; Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arterioscler Thromb Vasc Biol 2011,31(2),416-422","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000347122","volume":"124","author":"Torngren K.","year":"2013","unstructured":"Torngren K.; Ohman J.; Salmi H.; Larsson J.; Erlinge D.; Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology 2013,124(4),252-258","journal-title":"Cardiology"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"5984847","DOI":"10.1155\/2019\/5984847","volume":"2019","author":"Ray A.","year":"2019","unstructured":"Ray A.; Najmi A.; Khandelwal G.; Sadasivam B.; Ticagrelor-Induced Prolongation of the QTc Interval. Case Rep Cardiol 2019,2019,5984847","journal-title":"Case Rep Cardiol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1161\/ATVBAHA.118.310955","volume":"39","author":"Majithia A.","year":"2019","unstructured":"Majithia A.; Bhatt D.L.; Novel antiplatelet therapies for atherothrombotic diseases. Arterioscler Thromb Vasc Biol 2019,39(4),546-557","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","volume":"119","author":"Valgimigli M.","year":"2009","unstructured":"Valgimigli M.; Campo G.; de Cesare N.; Meliga E.; Vranckx P.; Furgieri A.; Angiolillo D.J.; Sabat\u00e8 M.; Hamon M.; Repetto A.; Colangelo S.; Brugaletta S.; Parrinello G.; Percoco G.; Ferrari R.; Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and\/or Resistance to Clopidogrel study. Circulation Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and\/or Resistance to Clopidogrel (3T\/2R) Investigators2009,119(25),3215-3222","journal-title":"Circulation"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ehj.2003.10.013","volume":"25","author":"Patrono C.","year":"2004","unstructured":"Patrono C.; Bachmann F.; Baigent C.; Bode C.; De Caterina R.; Charbonnier B.; Fitzgerald D.; Hirsh J.; Husted S.; Kvasnicka J.; Montalescot G.; Garc\u00eda Rodr\u00edguez L.A.; Verheugt F.; Vermylen J.; Wallentin L.; Priori S.G.; Alonso Garcia M.A.; Blanc J.J.; Budaj A.; Cowie M.; Dean V.; Deckers J.; Fern\u00e1ndez Burgos E.; Lekakis J.; Lindahl B.; Mazzotta G.; Morais J.; Oto A.; Smiseth O.A.; Morais J.; Deckers J.; Ferreira R.; Mazzotta G.; Steg P.G.; Teixeira F.; Wilcox R.; Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J European Society of Cardiology2004,25(2),166-181","journal-title":"Eur Heart J"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000209262","volume":"27","author":"Chamorro A.","year":"2009","unstructured":"Chamorro A.; TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 2009,27(3): (Suppl. 3),20-27","journal-title":"Cerebrovasc Dis"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/j.1538-7836.2010.04020.x","volume":"8","author":"Fiessinger J.N.","year":"2010","unstructured":"Fiessinger J.N.; Bounameaux H.; Cairols M.A.; Clement D.L.; Coccheri S.; Fletcher J.P.; Hoffmann U.; Turpie A.G.G.; Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. J Thromb Haemost TAIPAD investigators2010,8(11),2369-2376","journal-title":"J Thromb Haemost"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1159\/000212671","volume":"27","author":"Bousser M.G.","year":"2009","unstructured":"Bousser M.G.; Amarenco P.; Chamorro A.; Fisher M.; Ford I.; Fox K.; Hennerici M.G.; Mattle H.P.; Rothwell P.M.; Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg\/day versus aspirin 100 mg\/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis PERFORM Study Investigators2009,27(5),509-518","journal-title":"Cerebrovasc Dis"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejvs.2007.01.004","volume":"34","author":"Fontana P.","year":"2007","unstructured":"Fontana P.; Reny J-L.; New antiplatelet strategies in atherothrombosis and their indications. Eur J Vasc Endovasc Surg 2007,34(1),10-17","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","volume":"367","author":"Halkes P.H.A.","year":"2006","unstructured":"Halkes P.H.A.; van Gijn J.; Kappelle L.J.; Koudstaal P.J.; Algra A.; Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet ESPRIT Study Group2006,367(9523),1665-1673","journal-title":"Lancet"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","volume":"359","author":"Sacco R.L.","year":"2008","unstructured":"Sacco R.L.; Diener H.C.; Yusuf S.; Cotton D.; Ounpuu S.; Lawton W.A.; Palesch Y.; Martin R.H.; Albers G.W.; Bath P.; Bornstein N.; Chan B.P.; Chen S.T.; Cunha L.; Dahl\u00f6f B.; De Keyser J.; Donnan G.A.; Estol C.; Gorelick P.; Gu V.; Hermansson K.; Hilbrich L.; Kaste M.; Lu C.; Machnig T.; Pais P.; Roberts R.; Skvortsova V.; Teal P.; Toni D.; Vandermaelen C.; Voigt T.; Weber M.; Yoon B.W.; Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med PRoFESS Study Group2008,359(12),1238-1251","journal-title":"N Engl J Med"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/CIRCINTERVENTIONS.109.880179","volume":"3","author":"Jeong Y-H.","year":"2010","unstructured":"Jeong Y-H.; Hwang J-Y.; Kim I-S.; Park Y.; Hwang S-J.; Lee S-W.; Kwak C.H.; Park S-W.; Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010,3(1),17-26","journal-title":"Circ Cardiovasc Interv"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/j.1538-7836.2012.04869.x","volume":"10","author":"Capodanno D.","year":"2012","unstructured":"Capodanno D.; Bhatt D.L.; Goto S.; O\u2019Donoghue M.L.; Moliterno D.J.; Tamburino C.; Angiolillo D.J.; Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost 2012,10(10),2006-2015","journal-title":"J Thromb Haemost"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","volume":"123","author":"Wiviott S.D.","year":"2011","unstructured":"Wiviott S.D.; Flather M.D.; O\u2019Donoghue M.L.; Goto S.; Fitzgerald D.J.; Cura F.; Aylward P.; Guetta V.; Dudek D.; Contant C.F.; Angiolillo D.J.; Bhatt D.L.; Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin\u2013Coronary Artery Disease Trial. Circulation LANCELOT-CAD Investigators2011,123(17),1854-1863","journal-title":"Circulation"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/blood-2014-09-599910","volume":"125","author":"Aisiku O.","year":"2015","unstructured":"Aisiku O.; Peters C.G.; De Ceunynck K.; Ghosh C.C.; Dilks J.R.; Fustolo-Gunnink S.F.; Huang M.; Dockendorff C.; Parikh S.M.; Flaumenhaft R.; Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood 2015,125(12),1976-1985","journal-title":"Blood"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.112.091918","volume":"126","author":"Zhang P.","year":"2012","unstructured":"Zhang P.; Gruber A.; Kasuda S.; Kimmelstiel C.; O\u2019Callaghan K.; Cox D.H.; Bohm A.; Baleja J.D.; Covic L.; Kuliopulos A.; Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 2012,126(1),83-91","journal-title":"Circulation"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","volume":"38","author":"Wilson S.J.","year":"2018","unstructured":"Wilson S.J.; Ismat F.A.; Wang Z.; Cerra M.; Narayan H.; Raftis J.; Gray T.J.; Connell S.; Garonzik S.; Ma X.; Yang J.; Newby D.E.; PAR4 (protease-activated receptor 4) antagonism with bms-986120 inhibits human ex vivo thrombus formation. Arterioscler Thromb Vasc Biol 2018,38(2),448-456","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=136","unstructured":"Safety and efficacy study of a protease activated receptor-4 antagonist being tested to reduce the chances of having additional strokes or \u201cmini strokes.\u201d  https:\/\/clinicaltrials. gov\/ct2\/show\/NCT02671461"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/ATVBAHA.118.311758","volume":"39","author":"Lin Y.C.","year":"2019","unstructured":"Lin Y.C.; Ko Y.C.; Hung S.C.; Lin Y.T.; Lee J.H.; Tsai J.Y.; Kung P.H.; Tsai M.C.; Chen Y.F.; Wu C.C.; Selective inhibition of par4 (protease-activated receptor 4)-mediated platelet activation by a synthetic nonanticoagulant heparin analog. Arterioscler Thromb Vasc Biol 2019,39(4),694-703","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jjcc.2017.03.005","volume":"70","author":"Matoba T.","year":"2017","unstructured":"Matoba T.; Koga J.I.; Nakano K.; Egashira K.; Tsutsui H.; Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease. J Cardiol 2017,70(3),206-211","journal-title":"J Cardiol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/nnm.16.3","volume":"11","author":"Karimi M.","year":"2016","unstructured":"Karimi M.; Zare H.; Bakhshian Nik A.; Yazdani N.; Hamrang M.; Mohamed E.; Sahandi Zangabad P.; Moosavi Basri S.M.; Bakhtiari L.; Hamblin M.R.; Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine (Lond) 2016,11(5),513-530","journal-title":"Nanomedicine (Lond)"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1155\/2019\/3702518","volume":"2019","author":"Lombardo D.","year":"2019","unstructured":"Lombardo D.; Kiselev M.A.; Caccamo M.T.; Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine. J Nanomater 2019,2019,26","journal-title":"J Nanomater"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.7150\/thno.26284","volume":"8","author":"Bejarano J.","year":"2018","unstructured":"Bejarano J.; Navarro-Marquez M.; Morales-Zavala F.; Morales J.O.; Garcia-Carvajal I.; Araya-Fuentes E.; Flores Y.; Verdejo H.E.; Castro P.F.; Lavandero S.; Kogan M.J.; Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics 2018,8(17),4710-4732","journal-title":"Theranostics"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fbioe.2019.00489","volume":"7","author":"Deng Y.","year":"2020","unstructured":"Deng Y.; Zhang X.; Shen H.; He Q.; Wu Z.; Liao W.; Yuan M.; Application of the nano-drug delivery system in treatment of cardiovascular diseases. Front Bioeng Biotechnol 2020,7,489","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.thromres.2014.05.009","volume":"134","author":"Sathler P.C.","year":"2014","unstructured":"Sathler P.C.; Louren\u00e7o A.L.; Rodrigues C.R.; da Silva L.C.R.P.; Cabral L.M.; Jord\u00e3o A.K.; Cunha A.C.; Vieira M.C.B.; Ferreira V.F.; Carvalho-Pinto C.E.; Kang H.C.; Castro H.C.; \nin vitro and in vivo analysis of the antithrombotic and toxicological profile of new antiplatelets N-acylhydrazone derivatives and development of nanosystems: determination of novel NAH derivatives antiplatelet and nanotechnological approach. Thromb Res 2014,134(2),376-383","journal-title":"Thromb Res"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/ATVBAHA.118.311569","volume":"39","author":"Flores A.M.","year":"2019","unstructured":"Flores A.M.; Ye J.; Jarr K-U.; Hosseini-Nassab N.; Smith B.R.; Leeper N.J.; Nanoparticle therapy for vascular diseases. Arterioscler Thromb Vasc Biol 2019,39(4),635-646","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"59","DOI":"10.15171\/bi.2018.08","volume":"8","author":"Nakhlband A.","year":"2018","unstructured":"Nakhlband A.; Eskandani M.; Omidi Y.; Saeedi N.; Ghaffari S.; Barar J.; Garjani A.; Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective. Bioimpacts 2018,8(1),59-75","journal-title":"Bioimpacts"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.maturitas.2011.12.014","volume":"73","author":"Psarros C.","year":"2012","unstructured":"Psarros C.; Lee R.; Margaritis M.; Antoniades C.; Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Maturitas 2012,73(1),52-60","journal-title":"Maturitas"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s13204-018-0856-z","volume":"8","author":"Chandarana M.","year":"2018","unstructured":"Chandarana M.; Curtis A.; Hoskins C.; The use of nanotechnology in cardiovascular disease. Appl Nanosci 2018,8,1607-1619","journal-title":"Appl Nanosci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/jphp.13092","volume":"71","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Koradia A.; Kamato D.; Popat A.; Little P.J.; Ta H.T.; Treatment of atherosclerotic plaque: perspectives on theranostics. J Pharm Pharmacol 2019,71(7),1029-1043","journal-title":"J Pharm Pharmacol"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-019-0068-3","volume":"4","author":"Singh A.P.","year":"2019","unstructured":"Singh A.P.; Biswas A.; Shukla A.; Maiti P.; Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Sig Transduct Target Ther 2019,4,33","journal-title":"Sig Transduct Target Ther"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bioactmat.2017.11.002","volume":"2","author":"Jiang W.","year":"2017","unstructured":"Jiang W.; Rutherford D.; Vuong T.; Liu H.; Nanomaterials for treating cardiovascular diseases: A review. Bioact Mater 2017,2(4),185-198","journal-title":"Bioact Mater"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1039\/c2cs15327k","volume":"41","author":"Elsabahy M.","year":"2012","unstructured":"Elsabahy M.; Wooley K.L.; Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 2012,41(7),2545-2561","journal-title":"Chem Soc Rev"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11051-013-1529-1","volume":"15","author":"Karagkiozaki V.","year":"2013","unstructured":"Karagkiozaki V.; Nanomedicine highlights in atherosclerosis. J Nanopart Res 2013,15(4),1-17","journal-title":"J Nanopart Res"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ejpb.2015.03.033","volume":"97","author":"Beck-Broichsitter M.","year":"2015","unstructured":"Beck-Broichsitter M.; Nicolas J.; Couvreur P.; Design attributes of long-circulating polymeric drug delivery vehicles. Eur J Pharm Biopharm 2015,97(Pt B),304-317","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=154","first-page":"15998","volume":"5","author":"Giannouli M.","year":"2018","unstructured":"Giannouli M.; Karagkiozaki V.; Pappa F.; Moutsios I.; Gravalidis C.; Logothetidis S.; Fabrication of quercetin-loaded PLGA nanoparticles via electrohydrodynamic atomization for cardiovascular disease. Materials Today: Proceedings 2018,5(8),15998-16005","journal-title":"Materials Today: Proceedings"},{"key":"ref=155","first-page":"102","volume":"19","author":"Bakola V.","year":"2019","unstructured":"Bakola V.; Tsiapla A.R.; Karagkiozaki V.; Pappa F.; Pavlidou E.; Moutsios I.; Gravalidis C.; Logothetidis S.; Electrospray encapsulation of antithrombotic drug into poly (l-lactic acid) nanoparticles for cardiovascular applications. Materials Today: Proceedings 2019,19(1),102-109","journal-title":"Materials Today: Proceedings"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.msec.2018.10.029","volume":"94","author":"Gomes M.L.S.","year":"2019","unstructured":"Gomes M.L.S.; da Silva Nascimento N.; Borsato D.M.; Pretes A.P.; Nadal J.M.; Novatski A.; Gomes R.Z.; Fernandes D.; Farago P.V.; Zanin S.M.W.; Long-lasting anti-platelet activity of cilostazol from poly(\u03b5-caprolactone)-poly(ethylene glycol) blend nanocapsules. Mater Sci Eng C 2019,94,694-702","journal-title":"Mater Sci Eng C"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.jvs.2015.08.086","volume":"64","author":"Palekar R.U.","year":"2016","unstructured":"Palekar R.U.; Vemuri C.; Marsh J.N.; Arif B.; Wickline S.A.; Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models. J Vasc Surg 2016,64(5),1459-1467","journal-title":"J Vasc Surg"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ijpharm.2017.06.091","volume":"529","author":"Al Meslmani B.M.","year":"2017","unstructured":"Al Meslmani B.M.; Mahmoud G.F.; Bakowsky U.; Development of expanded polytetrafluoroethylene cardiovascular graft platform based on immobilization of poly lactic-co-glycolic acid nanoparticles using a wet chemical modification technique. Int J Pharm 2017,529(1-2),238-244","journal-title":"Int J Pharm"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/pharmaceutics11050222","volume":"11","author":"Son G-H.","year":"2019","unstructured":"Son G-H.; Na Y-G.; Huh H.W.; Wang M.; Kim M-K.; Han M-G.; Byeon J-J.; Lee H-K.; Cho C-W.; Systemic design and evaluation of ticagrelor-loaded nanostructured lipid carriers for enhancing bioavailability and antiplatelet activity. Pharmaceutics 2019,11(5),222-239","journal-title":"Pharmaceutics"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1248\/cpb.c18-00615","volume":"66","author":"El-Laithy H.M.","year":"2018","unstructured":"El-Laithy H.M.; Badawi A.; Abdelmalak N.S.; El-Sayyad N.; Cubosomes as oral drug delivery systems: A promising approach for enhancing the release of clopidogrel bisulphate in the intestine. Chem Pharm Bull (Tokyo) 2018,66(12),1165-1173","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1389450117666160208144143","volume":"19","author":"Jain A.","year":"2018","unstructured":"Jain A.; Jain S.K.; Stimuli-responsive smart liposomes in cancer targeting. Curr Drug Targets 2018,19(3),259-270","journal-title":"Curr Drug Targets"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.actbio.2018.01.038","volume":"70","author":"Zhang N.","year":"2018","unstructured":"Zhang N.; Li C.; Zhou D.; Ding C.; Jin Y.; Tian Q.; Meng X.; Pu K.; Zhu Y.; Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis. Acta Biomater 2018,70,227-236","journal-title":"Acta Biomater"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijpharm.2010.04.027","volume":"394","author":"Jain K.","year":"2010","unstructured":"Jain K.; Kesharwani P.; Gupta U.; Jain N.K.; Dendrimer toxicity: Let\u2019s meet the challenge. Int J Pharm 2010,394(1-2),122-142","journal-title":"Int J Pharm"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.progpolymsci.2013.07.005","volume":"39","author":"Kesharwani P.","year":"2014","unstructured":"Kesharwani P.; Jain K.; Jain N.K.; Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2014,39(2),268-307","journal-title":"Prog Polym Sci"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ijpharm.2018.07.030","volume":"548","author":"Sherje A.P.","year":"2018","unstructured":"Sherje A.P.; Jadhav M.; Dravyakar B.R.; Kadam D.; Dendrimers: A versatile nanocarrier for drug delivery and targeting. Int J Pharm 2018,548(1),707-720","journal-title":"Int J Pharm"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/jbm.a.36375","volume":"106","author":"Zhang S-F.","year":"2018","unstructured":"Zhang S-F.; L\u00fc S.; Gao C.; Yang J.; Yan X.; Li T.; Wen N.; Huang M.; Liu M.; Multiarm-polyethylene glycol-polyglutamic acid peptide dendrimer: Design, synthesis, and dissolving thrombus. J Biomed Mater Res A 2018,106(6),1687-1696","journal-title":"J Biomed Mater Res A"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.colsurfb.2017.08.009","volume":"159","author":"Zhang S-F.","year":"2017","unstructured":"Zhang S-F.; Gao C.; L\u00fc S.; He J.; Liu M.; Wu C.; Liu Y.; Zhang X.; Liu Z.; Synthesis of PEGylated polyglutamic acid peptide dendrimer and its application in dissolving thrombus. Colloids Surf B Biointerfaces 2017,159,284-292","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"e0182997","DOI":"10.1371\/journal.pone.0182997","volume":"12","author":"Paar M.","year":"2017","unstructured":"Paar M.; Rossmann C.; Nusshold C.; Wagner T.; Schlagenhauf A.; Leschnik B.; Oettl K.; Koestenberger M.; Cvirn G.; Hallstr\u00f6m S.; Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS One 2017,12(8),e0182997","journal-title":"PLoS One"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"110716","DOI":"10.1016\/j.jinorgbio.2019.110716","volume":"198","author":"Al-Harthi S.","year":"2019","unstructured":"Al-Harthi S.; Lachowicz J.I.; Nowakowski M.E.; Jaremko M.; Jaremko \u0141.; Towards the functional high-resolution coordination chemistry of blood plasma human serum albumin. J Inorg Biochem 2019,198,110716","journal-title":"J Inorg Biochem"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/ATVBAHA.119.313681","volume":"40","author":"Ronit A.","year":"2020","unstructured":"Ronit A.; Kirkegaard-Klitbo D.M.; Dohlmann T.L.; Lundgren J.; Sabin C.A.; Phillips A.N.; Nordestgaard B.G.; Afzal S.; Plasma albumin and incident cardiovascular disease: results from the cgps and an updated meta-analysis. Arterioscler Thromb Vasc Biol 2020,40(2),473-482","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cardfail.2011.02.010","volume":"17","author":"Arques S.","year":"2011","unstructured":"Arques S.; Ambrosi P.; Human serum albumin in the clinical syndrome of heart failure. J Card Fail 2011,17(6),451-458","journal-title":"J Card Fail"},{"key":"ref=172","first-page":"46","volume":"4","author":"Belousov A.","year":"2019","unstructured":"Belousov A.; Albumin and its Application. Mathews J Cas Rep 2019,4(1),46","journal-title":"Mathews J Cas Rep"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"e02879","DOI":"10.1016\/j.heliyon.2019.e02879","volume":"5","author":"Bteich M.","year":"2019","unstructured":"Bteich M.; An overview of albumin and alpha-1-acid glycoprotein main characteristics: highlighting the roles of amino acids in binding kinetics and molecular interactions. Heliyon 2019,5(11),e02879","journal-title":"Heliyon"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"6132542","DOI":"10.1155\/2019\/6132542","volume":"2019","author":"Kim S.H.","year":"2019","unstructured":"Kim S.H.; Youn C.S.; Kim H.J.; Choi S.P.; Prognostic value of serum albumin at admission for neurologic outcome with targeted temperature management after cardiac arrest. Emerg Med Int 2019,2019,6132542","journal-title":"Emerg Med Int"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"e0219044","DOI":"10.1371\/journal.pone.0219044","volume":"14","author":"Suzuki S.","year":"2019","unstructured":"Suzuki S.; Hashizume N.; Kanzaki Y.; Maruyama T.; Kozuka A.; Yahikozawa K.; Prognostic significance of serum albumin in patients with stable coronary artery disease treated by percutaneous coronary intervention. PLoS One 2019,14(7),e0219044","journal-title":"PLoS One"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/152308601300185241","volume":"3","author":"Bourdon E.","year":"2001","unstructured":"Bourdon E.; Blache D.; The importance of proteins in defense against oxidation. Antioxid Redox Signal 2001,3(2),293-311","journal-title":"Antioxid Redox Signal"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/0049-3848(79)90105-1","volume":"16","author":"J\u00f8orgensen K.A.","year":"1979","unstructured":"J\u00f8orgensen K.A.; Stoffersen E.; Heparin like activity of albumin. Thromb Res 1979,16(3-4),569-574","journal-title":"Thromb Res"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0049-3848(80)90289-3","volume":"17","author":"J\u00f8rgensen K.A.","year":"1980","unstructured":"J\u00f8rgensen K.A.; Stoffersen E.; On the inhibitory effect of albumin on platelet aggregation. Thromb Res 1980,17(1-2),13-18","journal-title":"Thromb Res"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1758-5996-3-11","volume":"3","author":"Frei E.","year":"2011","unstructured":"Frei E.; Albumin binding ligands and albumin conjugate uptake by cancer cells. Diabetol Metab Syndr 2011,3(1),11","journal-title":"Diabetol Metab Syndr"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12011-014-0165-7","volume":"163","author":"Sun J.","year":"2015","unstructured":"Sun J.; Huang Y.; Zheng C.; Zhou Y.; Liu Y.; Liu J.; Ruthenium (II) complexes interact with human serum albumin and induce apoptosis of tumor cells. Biol Trace Elem Res 2015,163(1-2),266-274","journal-title":"Biol Trace Elem Res"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2012.11.034","volume":"227","author":"Ishii H.","year":"2013","unstructured":"Ishii H.; Aoyama T.; Takahashi H.; Kamoi D.; Tanaka M.; Yoshikawa D.; Hayashi M.; Matsubara T.; Murohara T.; Serum albumin and C-reactive protein levels predict clinical outcome in hemodialysis patients undergoing endovascular therapy for peripheral artery disease. Atherosclerosis 2013,227(1),130-134","journal-title":"Atherosclerosis"},{"key":"ref=182","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1160\/TH09-12-0856","volume":"104","author":"Folsom A.R.","year":"2010","unstructured":"Folsom A.R.; Lutsey P.L.; Heckbert S.R.; Cushman M.; Folsom A.R.; Serum albumin and risk of venous thromboembolism. Thromb Haemost 2010,104(1),100-104","journal-title":"Thromb Haemost"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"ofy291","DOI":"10.1093\/ofid\/ofy291","volume":"5","author":"Dirajlal-Fargo S.","year":"2018","unstructured":"Dirajlal-Fargo S.; Kulkarni M.; Bowman E.; Shan L.; Sattar A.; Funderburg N.; McComsey G.A.; Serum albumin is associated with higher inflammation and carotid atherosclerosis in treated human immunodeficiency virus infection. Open Forum Infect Dis 2018,5(11),ofy291","journal-title":"Open Forum Infect Dis"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.2147\/IJN.S229992","volume":"14","author":"Huang Y.","year":"2019","unstructured":"Huang Y.; Deng S.; Luo X.; Liu Y.; Xu W.; Pan J.; Wang M.; Xia Z.; Evaluation of intestinal absorption mechanism and pharmacokinetics of curcumin-loaded galactosylated albumin nanoparticles. Int J Nanomedicine 2019,14,9721-9730","journal-title":"Int J Nanomedicine"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fchem.2018.00271","volume":"6","author":"Cova T.F.","year":"2018","unstructured":"Cova T.F.; Murtinho D.; Pais A.A.C.C.; Valente A.J.M.; Combining cellulose and cyclodextrins: fascinating designs for materials and pharmaceutics. Front Chem 2018,6,271","journal-title":"Front Chem"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ijpharm.2013.12.004","volume":"461","author":"Zafar N.","year":"2014","unstructured":"Zafar N.; Fessi H.; Elaissari A.; Cyclodextrin containing biodegradable particles: from preparation to drug delivery applications. Int J Pharm 2014,461(1-2),351-366","journal-title":"Int J Pharm"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"166","DOI":"10.34172\/apb.2020.022","volume":"10","author":"Gadade D.D.","year":"2020","unstructured":"Gadade D.D.; Pekamwar S.S.; Cyclodextrin Based Nanoparticles for Drug Delivery and Theranostics. Adv Pharm Bull 2020,10(2),166-183","journal-title":"Adv Pharm Bull"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1023\/A:1023088423667","volume":"44","author":"Loftsson T.","year":"2002","unstructured":"Loftsson T.; Cyclodextrins and the Biopharmaceutics classification system. J Incl Phenom Macrocycl Chem 2002,44,63-67","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.3762\/bjoc.12.261","volume":"12","author":"Leclercq L.","year":"2016","unstructured":"Leclercq L.; Interactions between cyclodextrins and cellular components: Towards greener medical applications? Beilstein J Org Chem 2016,12,2644-2662","journal-title":"Beilstein J Org Chem"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"107620","DOI":"10.1016\/j.pharmthera.2020.107620","volume":"214","author":"Mahjoubin-Tehran M.","year":"2020","unstructured":"Mahjoubin-Tehran M.; Kovanen P.T.; Xu S.; Jamialahmadi T.; Sahebkar A.; Cyclodextrins: Potential therapeutics against atherosclerosis. Pharmacol Ther 2020,214,107620","journal-title":"Pharmacol Ther"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00249-007-0207-6","volume":"36","author":"Roux M.","year":"2007","unstructured":"Roux M.; Perly B.; Djeda\u00efni-Pilard F.; Self-assemblies of amphiphilic cyclodextrins. Eur Biophys J 2007,36(8),861-867","journal-title":"Eur Biophys J"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1021\/js960213f","volume":"86","author":"Irie T.","year":"1997","unstructured":"Irie T.; Uekama K.; Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997,86(2),147-162","journal-title":"J Pharm Sci"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1021\/cr970025p","volume":"98","author":"Uekama K.","year":"1998","unstructured":"Uekama K.; Hirayama F.; Irie T.; Cyclodextrin drug carrier systems. Chem Rev 1998,98(5),2045-2076","journal-title":"Chem Rev"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.addr.2013.05.001","volume":"65","author":"Zhang J.","year":"2013","unstructured":"Zhang J.; Ma P.X.; Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective. Adv Drug Deliv Rev 2013,65(9),1215-1233","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"579","DOI":"10.7150\/thno.7688","volume":"4","author":"Silva A.K.","year":"2014","unstructured":"Silva A.K.; Letourneur D.; Chauvierre C.; Chauvierre C.; Polysaccharide nanosystems for future progress in cardiovascular pathologies. Theranostics 2014,4(6),579-591","journal-title":"Theranostics"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/0883911515585184","volume":"30","author":"Fu Y.","year":"2015","unstructured":"Fu Y.; Wang X.; Zhang Y.; Liu Z.; Xue W.; Effect of cyclodextrins on the structure and functions of blood components in vitro. J Bioact Compat Polym 2015,30(5),541-554","journal-title":"J Bioact Compat Polym"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0891-5849(95)02173-6","volume":"20","author":"Berliner J.A.","year":"1996","unstructured":"Berliner J.A.; Heinecke J.W.; The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996,20(5),707-727","journal-title":"Free Radic Biol Med"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"27450","DOI":"10.1074\/jbc.271.44.27450","volume":"271","author":"Kritharides L.","year":"1996","unstructured":"Kritharides L.; Kus M.; Brown A.J.; Jessup W.; Dean R.T.; Hydroxypropyl-beta-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells. J Biol Chem 1996,271(44),27450-27455","journal-title":"J Biol Chem"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/eurheartj\/ehr054","volume":"32","author":"Michel J.B.","year":"2011","unstructured":"Michel J.B.; Virmani R.; Arbustini E.; Pasterkamp G.; Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J 2011,32(16),1977-1985","journal-title":"Eur Heart J"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/sj.ki.5000263","volume":"69","author":"Meyrier A.","year":"2006","unstructured":"Meyrier A.; Cholesterol crystal embolism: diagnosis and treatment. Kidney Int 2006,69(8),1308-1312","journal-title":"Kidney Int"},{"key":"ref=201","first-page":"11","volume":"10","author":"Martinic G.","year":"2011","unstructured":"Martinic G.; Cyclodextrins as potential human antiatherosclerotic agents. A comparative pilot study to determine the most optimum route of administration of Hydroxy-propyl-\u03b2-cyclodextrin (HP-\u03b2-CD) in the apolipoprotein-E deficient \u2018knockout\u2019 mouse: Part III. Determining the optimum concentration of oral HP-\u03b2-CD. Anim Technol Welf 2011,10(1),11-25","journal-title":"Anim Technol Welf"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"333ra50","DOI":"10.1126\/scitranslmed.aad6100","volume":"8","author":"Zimmer S.","year":"2016","unstructured":"Zimmer S.; Grebe A.; Bakke S.S.; Bode N.; Halvorsen B.; Ulas T.; Skjelland M.; De Nardo D.; Labzin L.I.; Kerksiek A.; Hempel C.; Heneka M.T.; Hawxhurst V.; Fitzgerald M.L.; Trebicka J.; Bj\u00f6rkhem I.; Gustafsson J.A.; Westerterp M.; Tall A.R.; Wright S.D.; Espevik T.; Schultze J.L.; Nickenig G.; L\u00fctjohann D.; Latz E.; Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med 2016,8(333),333ra50","journal-title":"Sci Transl Med"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.4049\/jimmunol.1700302","volume":"199","author":"Bakke S.S.","year":"2017","unstructured":"Bakke S.S.; Aune M.H.; Niyonzima N.; Pilely K.; Ryan L.; Skjelland M.; Garred P.; Aukrust P.; Halvorsen B.; Latz E.; Dam\u00e5s J.K.; Mollnes T.E.; Espevik T.; Cyclodextrin reduces cholesterol crystal-induced inflammation by modulating complement activation. J Immunol 2017,199(8),2910-2920","journal-title":"J Immunol"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2019.01.034","volume":"283","author":"Pilely K.","year":"2019","unstructured":"Pilely K.; Bakke S.S.; Palarasah Y.; Skjoedt M.O.; Bartels E.D.; Espevik T.; Garred P.; Garred P.; Alpha-cyclodextrin inhibits cholesterol crystal-induced complement-mediated inflammation: A potential new compound for treatment of atherosclerosis. Atherosclerosis 2019,283,35-42","journal-title":"Atherosclerosis"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/FJC.0000000000000660","volume":"73","author":"Wang H.","year":"2019","unstructured":"Wang H.; Zhang X.; Yu B.; Peng X.; Liu Y.; Wang A.; Zhao D.; Pang D.; OuYang H.; Tang X.; Cyclodextrin ameliorates the progression of atherosclerosis via increasing high-density lipoprotein cholesterol plasma levels and anti-inflammatory effects in rabbits. J Cardiovasc Pharmacol 2019,73(5),334-342","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1039\/c2cc17852d","volume":"48","author":"Li H.","year":"2012","unstructured":"Li H.; El-Dakdouki M.H.; Zhu D.C.; Abela G.S.; Huang X.; Synthesis of \u03b2-cyclodextrin conjugated superparamagnetic iron oxide nanoparticles for selective binding and detection of cholesterol crystals. Chem Commun (Camb) 2012,48(28),3385-3387","journal-title":"Chem Commun (Camb)"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12944-016-0284-6","volume":"15","author":"Amar M.J.","year":"2016","unstructured":"Amar M.J.; Kaler M.; Courville A.B.; Shamburek R.; Sampson M.; Remaley A.T.; Randomized double blind clinical trial on the effect of oral \u03b1-cyclodextrin on serum lipids. Lipids Health Dis 2016,15(1),115","journal-title":"Lipids Health Dis"},{"key":"ref=208","author":"Wang L.","year":"2018","unstructured":"Wang L.; Zhang X.; Niu Y.; Ahmed A.F.; Wang J.; Kang W.; Anticoagulant activity of two novel polysaccharides from flowers of Apocynum venetum L. Int J Biol Macromol 2018","journal-title":"Int J Biol Macromol"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/md17040195","volume":"17","author":"Guan R.","year":"2019","unstructured":"Guan R.; Peng Y.; Zhou L.; Zheng W.; Liu X.; Wang P.; Yuan Q.; Gao N.; Zhao L.; Zhao J.; Precise Structure and Anticoagulant Activity of Fucosylated Glycosaminoglycan from Apostichopus japonicus: Analysis of Its Depolymerized Fragments. Mar Drugs 2019,17(4),195-207","journal-title":"Mar Drugs"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3390\/molecules25030710","volume":"25","author":"Bian C.","year":"2020","unstructured":"Bian C.; Wang Z.; Shi J.; Extraction Optimization, Structural Characterization, and Anticoagulant Activity of Acidic Polysaccharides from Auricularia auricula-judae.\n Molecules 2020,25(3),710","journal-title":"Molecules"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"14786","DOI":"10.1021\/acsomega.0c01724","volume":"5","author":"Dhahri M.","year":"2020","unstructured":"Dhahri M.; Sioud S.; Dridi R.; Hassine M.; Boughattas N.A.; Almulhim F.; Al Talla Z.; Jaremko M.; Emwas A.M.; Extraction, characterization, and anticoagulant activity of a sulfated polysaccharide from bursatella leachii viscera. ACS Omega 2020,5(24),14786-14795","journal-title":"ACS Omega"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/md18010006","volume":"18","author":"Du Z.","year":"2019","unstructured":"Du Z.; Jia X.; Chen J.; Zhou S.; Chen J.; Liu X.; Cao X.; Zhong S.; Hong P.; Isolation and characterization of a heparin-like compound with potent anticoagulant and fibrinolytic activity from the clam Coelomactra antiquata.\n Mar Drugs 2019,18(1),6","journal-title":"Mar Drugs"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.procbio.2019.12.006","volume":"91","author":"Chahed L.","year":"2019","unstructured":"Chahed L.; Balti R.; Elhiss S.; Bouchemal N.; Ajzenberg N.; Ollivier V.; Chaubet F.; Maaroufi R.M.; Mansour M.B.; Anticoagulant activity of fucosylated chondroitin sulfate isolated from Cucumaria syracusana. Process Biochem 2019,91,149-157","journal-title":"Process Biochem"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.carbpol.2015.12.054","volume":"140","author":"Cai W.","year":"2016","unstructured":"Cai W.; Xu H.; Xie L.; Sun J.; Sun T.; Wu X.; Fu Q.; Purification, characterization and in vitro anticoagulant activity of polysaccharides from Gentiana scabra Bunge roots. Carbohydr Polym 2016,140,308-313","journal-title":"Carbohydr Polym"},{"key":"ref=215","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijbiomac.2018.11.044","volume":"123","author":"Ghlissi Z.","year":"2018","unstructured":"Ghlissi Z.; Krichen F.; Kallel R.; Amor I.B.; Boudawara T.; Gargouri J.; Zeghal K.; Hakim A.; Bougatef A.; Sahnoun Z.; Sulfated polysaccharide isolated from Globularia alypum L.: Structural characterization, in vivo and in vitro anticoagulant activity, and toxicological profile. Int J Biol Macromol 2018,123,335-342","journal-title":"Int J Biol Macromol"},{"key":"ref=216","first-page":"612352","volume":"2015","author":"Chen X.","year":"2015","unstructured":"Chen X.; Yang S.; Wang J.; Song L.; Xing R.; Liu S.; Yu H.; Li P.; Yu H.; Li P.; Sulfated polysaccharides isolated from cloned grateloupia filicina and their anticoagulant activity. BioMed Res Int 2015,2015,612352","journal-title":"BioMed Res Int"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"115844","DOI":"10.1016\/j.carbpol.2020.115844","volume":"233","author":"Yang W.","year":"2020","unstructured":"Yang W.; Chen D.; He Z.; Zhou L.; Cai Y.; Mao H.; Gao N.; Zuo Z.; Yin R.; Zhao J.; NMR characterization and anticoagulant activity of the oligosaccharides from the fucosylated glycosaminoglycan isolated from Holothuria coluber. Carbohydr Polym 2020,233,115844","journal-title":"Carbohydr Polym"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.carbpol.2017.06.128","volume":"174","author":"Ben Mansour M.","year":"2017","unstructured":"Ben Mansour M.; Balti R.; Ollivier V.; Ben Jannet H.; Chaubet F.; Maaroufi R.M.; Characterization and anticoagulant activity of a fucosylated chondroitin sulfate with unusually procoagulant effect from sea cucumber. Carbohydr Polym 2017,174,760-771","journal-title":"Carbohydr Polym"},{"key":"ref=219","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijbiomac.2018.10.129","volume":"121","author":"Mansour M.B.","year":"2018","unstructured":"Mansour M.B.; Balti R.; Yacoubi L.; Ollivier V.; Chaubet F.; Maaroufi R.M.; Primary structure and anticoagulant activity of fucoidan from the sea cucumber Holothuria polii. Int J Biol Macromol 2018,121,1145-53","journal-title":"Int J Biol Macromol"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.ijbiomac.2018.04.175","volume":"115","author":"Yang W.","year":"2018","unstructured":"Yang W.; Cai Y.; Yin R.; Lin L.; Li Z.; Wu M.; Zhao J.; Structural analysis and anticoagulant activities of two sulfated polysaccharides from the sea cucumber Holothuria coluber. Int J Biol Macromol 2018,115,1055-1062","journal-title":"Int J Biol Macromol"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/fsn3.1360","volume":"8","author":"Zhang X.","year":"2019","unstructured":"Zhang X.; Ma X.T.; Xu Y.; Jiang G.C.; Zhang J.L.; Liu X.J.; Yan X.H.; Extraction, purification, characterization, anticoagulant activity, and anticoagulant mechanism of polysaccharides from the heads of Hypomesus olidus.\n Food Sci Nutr 2019,8(2),849-861","journal-title":"Food Sci Nutr"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jfda.2016.08.011","volume":"25","author":"Zong S.","year":"2017","unstructured":"Zong S.; Ji J.; Li J.; Yang Q-H.; Ye M.; Physicochemical properties and anticoagulant activity of polyphenols derived from Lachnum singerianum. Yao Wu Shi Pin Fen Xi 2017,25(4),837-844","journal-title":"Yao Wu Shi Pin Fen Xi"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1039\/C9RA10853J","volume":"10","author":"Hu C.","year":"2020","unstructured":"Hu C.; Li H-X.; Zhang M-T.; Liu L-F.; Structure characterization and anticoagulant activity of a novel polysaccharide from Leonurus artemisia (Laur.) S. Y. Hu F. RSC Advances 2020,10(4),2254-2266","journal-title":"RSC Advances"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"115031","DOI":"10.1016\/j.carbpol.2019.115031","volume":"222","author":"Palhares L.C.G.F.","year":"2019","unstructured":"Palhares L.C.G.F.; Brito A.S.; de Lima M.A.; Nader H.B.; London J.A.; Barsukov I.L.; Andrade G.P.V.; Yates E.A.; Chavante S.F.; A further unique chondroitin sulfate from the shrimp Litopenaeus vannamei with antithrombin activity that modulates acute inflammation. Carbohydr Polym 2019,222,115031","journal-title":"Carbohydr Polym"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ijbiomac.2019.04.147","volume":"133","author":"Lin S.","year":"2019","unstructured":"Lin S.; Al-Wraikat M.; Niu L.; Zhou F.; Zhang Y.; Wang M.; Ren J.; Fan J.; Zhang B.; Wang L.; Degradation enhances the anticoagulant and antiplatelet activities of polysaccharides from Lycium barbarum L. leaves. Int J Biol Macromol 2019,133,674-682","journal-title":"Int J Biol Macromol"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.biopha.2016.03.027","volume":"80","author":"Sayari N.","year":"2016","unstructured":"Sayari N.; Balti R.; Ben Mansour M.; Ben Amor I.; Graiet I.; Gargouri J.; Bougatef A.; Anticoagulant properties and cytotoxic effect against HCT116 human colon cell line of sulfated glycosaminoglycans isolated from the Norway lobster (Nephrops norvegicus) shell. Biomed Pharmacother 2016,80,322-330","journal-title":"Biomed Pharmacother"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijbiomac.2019.06.116","volume":"136","author":"Song S.","year":"2019","unstructured":"Song S.; Wang L.; Wang L.; Yu Q.; Ai C.; Fu Y.; Yan C.; Wen C.; Zhu Z.; Structural characterization and anticoagulant activity of two polysaccharides from Patinopecten yessoensis viscera. Int J Biol Macromol 2019,136,579-585","journal-title":"Int J Biol Macromol"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ijbiomac.2019.05.036","volume":"134","author":"Bougatef H.","year":"2019","unstructured":"Bougatef H.; Krichen F.; Capitani F.; Amor I.B.; Gargouri J.; Maccari F.; Mantovani V.; Galeotti F.; Volpi N.; Bougatef A.; Sila A.; Purification, compositional analysis, and anticoagulant capacity of chondroitin sulfate\/dermatan sulfate from bone of corb (Sciaena umbra). Int J Biol Macromol 2019,134,405-412","journal-title":"Int J Biol Macromol"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"11538","DOI":"10.1039\/C9RA00959K","volume":"9","author":"Souissi N.","year":"2019","unstructured":"Souissi N.; Boughriba S.; Abdelhedi O.; Hamdi M.; Jridi M.; Li S.; Nasri M.; Extraction, structural characterization, and thermal and biomedical properties of sulfated polysaccharides from razor clam Solen marginatus. RSC Advances 2019,9(20),11538-11551","journal-title":"RSC Advances"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"101750","DOI":"10.1016\/j.algal.2019.101750","volume":"45","author":"Reis S.E.","year":"2020","unstructured":"Reis S.E.; Andrade R.G.C.; Accardo C.M.; Maia L.F.; Oliveira L.F.C.; Nader H.B.; Aguiar J.A.K.; Medeiros V.P.; Influence of sulfated polysaccharides from Ulva lactuca L. upon Xa and IIa coagulation factors and on venous blood clot formation. Algal Res 2020,45,101750","journal-title":"Algal Res"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450121666201027125303","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187248\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450121666201027125303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:03:20Z","timestamp":1660716200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187248\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":230,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666201027125303","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}